ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance
August 7, 2018 8:38 AM EDTANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.13, $0.21 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $47.3 million versus the consensus estimate of $51.42 million.
GUIDANCE:
ANI Pharma sees FY2018 EPS of $4.80-$5.27, versus the consensus... More



